Ashvattha Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ashvattha Therapeutics, Inc. - overview
Established
2015
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Founded in 2015 and based in California, US, Ashvattha Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of various diseases. In January 2025, Ashvattha Therapeutics, Inc. raised USD 50 million in venture funding co-led by returning investors Tribe Capital and Natural Capital.
Ashvattha Therapeutics, Inc. utilizes a proprietary Hydroxyl Dendrimer (HD) platform to produce novel HD therapeutics (hydroxyl dendrimer therapeutics) that selectively target the inflamed tissues or diseased cells in the human body. The company’s precision medicines can be used for the treatment of various therapeutical areas including neurology, ophthalmology, hyperinflammatory, and neuro-oncology. The firm’s product pipeline comprises OP-101, D-4517.
2, OP-801, and D6-B483. The company will use the April 2022 funding for the advancement of its pipeline of hydroxyl dendrimer therapeutics (HDTs), including other multiple clinical-stage programs.
Current Investors
EcoR1 Capital, Natural Capital, Sand Hill Angels
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Optometrists & Opticians Products and Services
Website
www.avttx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.